CA3082321A1 - Single domain antibodies that bind to cd137 - Google Patents

Info

Publication number

CA3082321A1

CA3082321A1 CA3082321A CA3082321A CA3082321A1 CA 3082321 A1 CA3082321 A1 CA 3082321A1 CA 3082321 A CA3082321 A CA 3082321A CA 3082321 A CA3082321 A CA 3082321A CA 3082321 A1 CA3082321 A1 CA 3082321A1

Authority

CA

Canada

Prior art keywords

seq

heavy chain

domain antibody

variable heavy

single variable

Prior art date

2017-11-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 108010003723 Single-Domain Antibodies Proteins 0.000 title claims description 113
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims abstract description 310
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims abstract description 248
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 31
• 238000011282 treatment Methods 0.000 claims abstract description 24
• 201000010099 disease Diseases 0.000 claims abstract description 17
• 230000027455 binding Effects 0.000 claims description 222
• 238000009739 binding Methods 0.000 claims description 222
• 210000004027 cell Anatomy 0.000 claims description 126
• 206010028980 Neoplasm Diseases 0.000 claims description 98
• 239000000427 antigen Substances 0.000 claims description 89
• 108091007433 antigens Proteins 0.000 claims description 89
• 102000036639 antigens Human genes 0.000 claims description 89
• 108090000623 proteins and genes Proteins 0.000 claims description 66
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 59
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 59
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 59
• 102000050327 human TNFRSF9 Human genes 0.000 claims description 56
• 238000000034 method Methods 0.000 claims description 52
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
• 150000007523 nucleic acids Chemical class 0.000 claims description 40
• 239000008194 pharmaceutical composition Substances 0.000 claims description 37
• 102000039446 nucleic acids Human genes 0.000 claims description 34
• 108020004707 nucleic acids Proteins 0.000 claims description 34
• 241000283984 Rodentia Species 0.000 claims description 28
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 25
• 230000011664 signaling Effects 0.000 claims description 24
• 108091006905 Human Serum Albumin Proteins 0.000 claims description 23
• 102000008100 Human Serum Albumin Human genes 0.000 claims description 23
• 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 23
• 201000011510 cancer Diseases 0.000 claims description 23
• 230000004913 activation Effects 0.000 claims description 20
• 230000009261 transgenic effect Effects 0.000 claims description 17
• 239000012634 fragment Substances 0.000 claims description 15
• 208000035475 disorder Diseases 0.000 claims description 14
• -1 cMet Proteins 0.000 claims description 13
• 230000001225 therapeutic effect Effects 0.000 claims description 13
• 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims description 12
• 241001465754 Metazoa Species 0.000 claims description 11
• 102000011769 Member 9 Tumor Necrosis Factor Receptor Superfamily Human genes 0.000 claims description 10
• 108010037274 Member 9 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 claims description 10
• 108700019146 Transgenes Proteins 0.000 claims description 10
• 239000013598 vector Substances 0.000 claims description 10
• 102000004190 Enzymes Human genes 0.000 claims description 9
• 108090000790 Enzymes Proteins 0.000 claims description 9
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 9
• 208000012902 Nervous system disease Diseases 0.000 claims description 8
• 208000025966 Neurological disease Diseases 0.000 claims description 8
• 208000026278 immune system disease Diseases 0.000 claims description 8
• 208000027866 inflammatory disease Diseases 0.000 claims description 8
• 206010020751 Hypersensitivity Diseases 0.000 claims description 7
• 206010052779 Transplant rejections Diseases 0.000 claims description 7
• 208000036142 Viral infection Diseases 0.000 claims description 7
• 208000026935 allergic disease Diseases 0.000 claims description 7
• 230000007815 allergy Effects 0.000 claims description 7
• 230000007812 deficiency Effects 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 7
• 210000000987 immune system Anatomy 0.000 claims description 7
• 238000002649 immunization Methods 0.000 claims description 7
• 238000004519 manufacturing process Methods 0.000 claims description 7
• 238000011830 transgenic mouse model Methods 0.000 claims description 7
• 230000009385 viral infection Effects 0.000 claims description 7
• 102000004127 Cytokines Human genes 0.000 claims description 6
• 108090000695 Cytokines Proteins 0.000 claims description 6
• 206010025323 Lymphomas Diseases 0.000 claims description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
• 230000001580 bacterial effect Effects 0.000 claims description 6
• 239000000126 substance Substances 0.000 claims description 6
• 239000003053 toxin Substances 0.000 claims description 6
• 231100000765 toxin Toxicity 0.000 claims description 6
• 108700012359 toxins Proteins 0.000 claims description 6
• 208000026310 Breast neoplasm Diseases 0.000 claims description 5
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
• 239000002202 Polyethylene glycol Substances 0.000 claims description 5
• 206010038389 Renal cancer Diseases 0.000 claims description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
• 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 5
• 239000003153 chemical reaction reagent Substances 0.000 claims description 5
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
• 230000001939 inductive effect Effects 0.000 claims description 5
• 201000010982 kidney cancer Diseases 0.000 claims description 5
• 229920001223 polyethylene glycol Polymers 0.000 claims description 5
• 102000009027 Albumins Human genes 0.000 claims description 4
• 108010088751 Albumins Proteins 0.000 claims description 4
• 206010006187 Breast cancer Diseases 0.000 claims description 4
• 208000017604 Hodgkin disease Diseases 0.000 claims description 4
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
• 230000010261 cell growth Effects 0.000 claims description 4
• 206010017758 gastric cancer Diseases 0.000 claims description 4
• 201000001441 melanoma Diseases 0.000 claims description 4
• 201000011549 stomach cancer Diseases 0.000 claims description 4
• BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 3
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 3
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 3
• 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 3
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
• 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 3
• 108010065524 CD52 Antigen Proteins 0.000 claims description 3
• 101150029707 ERBB2 gene Proteins 0.000 claims description 3
• 102100032530 Glypican-3 Human genes 0.000 claims description 3
• 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 3
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 3
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
• 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 3
• 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 3
• 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 3
• 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 3
• 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 3
• 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 3
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 3
• 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims description 3
• 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 3
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 3
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 3
• 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 3
• 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 3
• 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 3
• 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 3
• 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 3
• 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 3
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 3
• 102000003735 Mesothelin Human genes 0.000 claims description 3
• 108090000015 Mesothelin Proteins 0.000 claims description 3
• 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims description 3
• 102100034256 Mucin-1 Human genes 0.000 claims description 3
• 102100023123 Mucin-16 Human genes 0.000 claims description 3
• 208000034578 Multiple myelomas Diseases 0.000 claims description 3
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
• 206010060862 Prostate cancer Diseases 0.000 claims description 3
• 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
• 102100038081 Signal transducer CD24 Human genes 0.000 claims description 3
• 101001051488 Takifugu rubripes Neural cell adhesion molecule L1 Proteins 0.000 claims description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
• 208000032839 leukemia Diseases 0.000 claims description 3
• 201000005202 lung cancer Diseases 0.000 claims description 3
• 208000020816 lung neoplasm Diseases 0.000 claims description 3
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
• 201000002528 pancreatic cancer Diseases 0.000 claims description 3
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
• 230000001737 promoting effect Effects 0.000 claims description 3
• 101150047061 tag-72 gene Proteins 0.000 claims description 3
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
• 230000003612 virological effect Effects 0.000 claims description 3
• 206010005949 Bone cancer Diseases 0.000 claims description 2
• 208000018084 Bone neoplasm Diseases 0.000 claims description 2
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
• 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 2
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
• 206010027406 Mesothelioma Diseases 0.000 claims description 2
• 206010033128 Ovarian cancer Diseases 0.000 claims description 2
• 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
• 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
• 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
• 206010057644 Testis cancer Diseases 0.000 claims description 2
• 102000004338 Transferrin Human genes 0.000 claims description 2
• 108090000901 Transferrin Proteins 0.000 claims description 2
• 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
• 201000003761 Vaginal carcinoma Diseases 0.000 claims description 2
• 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
• 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 2
• 208000019065 cervical carcinoma Diseases 0.000 claims description 2
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
• 210000000750 endocrine system Anatomy 0.000 claims description 2
• 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
• 201000001343 fallopian tube carcinoma Diseases 0.000 claims description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
• 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
• 210000004962 mammalian cell Anatomy 0.000 claims description 2
• 210000002990 parathyroid gland Anatomy 0.000 claims description 2
• 206010038038 rectal cancer Diseases 0.000 claims description 2
• 201000001275 rectum cancer Diseases 0.000 claims description 2
• 201000000849 skin cancer Diseases 0.000 claims description 2
• 210000000813 small intestine Anatomy 0.000 claims description 2
• 201000003120 testicular cancer Diseases 0.000 claims description 2
• 208000008732 thymoma Diseases 0.000 claims description 2
• 210000001685 thyroid gland Anatomy 0.000 claims description 2
• 239000012581 transferrin Substances 0.000 claims description 2
• 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
• 208000023747 urothelial carcinoma Diseases 0.000 claims description 2
• 206010046766 uterine cancer Diseases 0.000 claims description 2
• 208000013013 vulvar carcinoma Diseases 0.000 claims description 2
• 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
• 239000011230 binding agent Substances 0.000 abstract description 30
• 238000001514 detection method Methods 0.000 abstract description 9
• 230000002265 prevention Effects 0.000 abstract description 7
• 239000003795 chemical substances by application Substances 0.000 description 907
• 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 108
• 101150062912 cct3 gene Proteins 0.000 description 108
• 241000699666 Mus <mouse, genus> Species 0.000 description 50
• 108010025592 aminoadipoyl-cysteinyl-allylglycine Proteins 0.000 description 50
• 235000001014 amino acid Nutrition 0.000 description 43
• 102000004169 proteins and genes Human genes 0.000 description 43
• 235000018102 proteins Nutrition 0.000 description 40
• 229940024606 amino acid Drugs 0.000 description 33
• 150000001413 amino acids Chemical class 0.000 description 31
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 29
• 125000005647 linker group Chemical group 0.000 description 29
• 102000004196 processed proteins & peptides Human genes 0.000 description 28
• 239000000203 mixture Substances 0.000 description 27
• 229920001184 polypeptide Polymers 0.000 description 25
• 230000000694 effects Effects 0.000 description 23
• 238000006467 substitution reaction Methods 0.000 description 23
• 125000003275 alpha amino acid group Chemical group 0.000 description 22
• CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 description 22
• 241000699670 Mus sp. Species 0.000 description 21
• 230000004048 modification Effects 0.000 description 20
• 238000012986 modification Methods 0.000 description 20
• 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 18
• 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 18
• 239000003814 drug Substances 0.000 description 18
• 230000009977 dual effect Effects 0.000 description 17
• 102200161322 rs11739136 Human genes 0.000 description 17
• 108060003951 Immunoglobulin Proteins 0.000 description 16
• 102000037865 fusion proteins Human genes 0.000 description 16
• 108020001507 fusion proteins Proteins 0.000 description 16
• 210000004602 germ cell Anatomy 0.000 description 16
• 102000018358 immunoglobulin Human genes 0.000 description 16
• 230000003993 interaction Effects 0.000 description 16
• 108010082808 4-1BB Ligand Proteins 0.000 description 15
• 125000000539 amino acid group Chemical group 0.000 description 15
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 14
• 238000003556 assay Methods 0.000 description 13
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
• 230000001270 agonistic effect Effects 0.000 description 12
• 239000000872 buffer Substances 0.000 description 12
• 239000002773 nucleotide Substances 0.000 description 12
• 125000003729 nucleotide group Chemical group 0.000 description 12
• 238000010790 dilution Methods 0.000 description 11
• 239000012895 dilution Substances 0.000 description 11
• 230000001404 mediated effect Effects 0.000 description 11
• 210000002966 serum Anatomy 0.000 description 11
• 229940124597 therapeutic agent Drugs 0.000 description 11
• 238000002560 therapeutic procedure Methods 0.000 description 11
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 10
• VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 10
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
• 108010002350 Interleukin-2 Proteins 0.000 description 10
• 102000000588 Interleukin-2 Human genes 0.000 description 10
• 102220502536 Platelet-activating factor acetylhydrolase IB subunit alpha2_G55E_mutation Human genes 0.000 description 10
• 238000010494 dissociation reaction Methods 0.000 description 10
• 230000005593 dissociations Effects 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• 238000003780 insertion Methods 0.000 description 10
• 230000037431 insertion Effects 0.000 description 10
• 230000004073 interleukin-2 production Effects 0.000 description 10
• 239000007788 liquid Substances 0.000 description 10
• 230000002829 reductive effect Effects 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 230000008685 targeting Effects 0.000 description 10
• JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 description 9
• 238000002965 ELISA Methods 0.000 description 9
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
• YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 9
• 210000004899 c-terminal region Anatomy 0.000 description 9
• 238000012217 deletion Methods 0.000 description 9
• 230000037430 deletion Effects 0.000 description 9
• 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 description 9
• 230000001965 increasing effect Effects 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 238000010561 standard procedure Methods 0.000 description 9
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
• 230000006044 T cell activation Effects 0.000 description 8
• 150000001875 compounds Chemical class 0.000 description 8
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
• 238000010186 staining Methods 0.000 description 8
• 108020004414 DNA Proteins 0.000 description 7
• 229920001213 Polysorbate 20 Polymers 0.000 description 7
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 7
• 230000013595 glycosylation Effects 0.000 description 7
• 238000006206 glycosylation reaction Methods 0.000 description 7
• 230000028993 immune response Effects 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 239000000178 monomer Substances 0.000 description 7
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 102220032394 rs104895290 Human genes 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• 102000050627 Glucocorticoid-Induced TNFR-Related Human genes 0.000 description 6
• 108700002054 Glucocorticoid-Induced TNFR-Related Proteins 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
• 239000005089 Luciferase Substances 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• 241000577979 Peromyscus spicilegus Species 0.000 description 6
• 108700008625 Reporter Genes Proteins 0.000 description 6
• 102000007562 Serum Albumin Human genes 0.000 description 6
• 108010071390 Serum Albumin Proteins 0.000 description 6
• 210000004443 dendritic cell Anatomy 0.000 description 6
• 239000000284 extract Substances 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 238000011534 incubation Methods 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 210000003712 lysosome Anatomy 0.000 description 6
• 230000001868 lysosomic effect Effects 0.000 description 6
• 239000006228 supernatant Substances 0.000 description 6
• 238000012360 testing method Methods 0.000 description 6
• 210000004881 tumor cell Anatomy 0.000 description 6
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
• 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 5
• 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 5
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
• 241001529936 Murinae Species 0.000 description 5
• 241000699660 Mus musculus Species 0.000 description 5
• 102220608182 Myosin-binding protein H_S84N_mutation Human genes 0.000 description 5
• 102000003945 NF-kappa B Human genes 0.000 description 5
• 108010057466 NF-kappa B Proteins 0.000 description 5
• 230000005867 T cell response Effects 0.000 description 5
• 102220477940 Triggering receptor expressed on myeloid cells 1_T25S_mutation Human genes 0.000 description 5
• 238000007792 addition Methods 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 229910052799 carbon Inorganic materials 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
• 239000012636 effector Substances 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 238000005259 measurement Methods 0.000 description 5
• 238000002703 mutagenesis Methods 0.000 description 5
• 231100000350 mutagenesis Toxicity 0.000 description 5
• 229910052698 phosphorus Inorganic materials 0.000 description 5
• 238000000159 protein binding assay Methods 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 230000006798 recombination Effects 0.000 description 5
• 238000005215 recombination Methods 0.000 description 5
• 102220169076 rs138407155 Human genes 0.000 description 5
• 102200010049 rs869025189 Human genes 0.000 description 5
• 238000012216 screening Methods 0.000 description 5
• 230000009870 specific binding Effects 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 238000005406 washing Methods 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• 239000012103 Alexa Fluor 488 Substances 0.000 description 4
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
• 108060001084 Luciferase Proteins 0.000 description 4
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 101710120037 Toxin CcdB Proteins 0.000 description 4
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
• 238000002835 absorbance Methods 0.000 description 4
• 239000008186 active pharmaceutical agent Substances 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• 230000000259 anti-tumor effect Effects 0.000 description 4
• 238000011319 anticancer therapy Methods 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 239000012131 assay buffer Substances 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 239000003623 enhancer Substances 0.000 description 4
• 238000000684 flow cytometry Methods 0.000 description 4
• 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 4
• 102000051144 human TNFSF9 Human genes 0.000 description 4
• 229910052739 hydrogen Inorganic materials 0.000 description 4
• 230000006698 induction Effects 0.000 description 4
• 230000010354 integration Effects 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 238000000520 microinjection Methods 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 230000009871 nonspecific binding Effects 0.000 description 4
• 238000002823 phage display Methods 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 229910052717 sulfur Inorganic materials 0.000 description 4
• 230000004614 tumor growth Effects 0.000 description 4
• 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 3
• 206010069754 Acquired gene mutation Diseases 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 3
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 3
• 108010074328 Interferon-gamma Proteins 0.000 description 3
• 229930182816 L-glutamine Natural products 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• 108091000080 Phosphotransferase Proteins 0.000 description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 108091008874 T cell receptors Proteins 0.000 description 3
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
• 102100040247 Tumor necrosis factor Human genes 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 230000006786 activation induced cell death Effects 0.000 description 3
• 230000008484 agonism Effects 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 239000003086 colorant Substances 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 229940127089 cytotoxic agent Drugs 0.000 description 3
• 210000002257 embryonic structure Anatomy 0.000 description 3
• 230000005284 excitation Effects 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 230000030279 gene silencing Effects 0.000 description 3
• 238000012226 gene silencing method Methods 0.000 description 3
• 238000010362 genome editing Methods 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 229940127121 immunoconjugate Drugs 0.000 description 3
• 230000002998 immunogenetic effect Effects 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 238000009169 immunotherapy Methods 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
• 229960000310 isoleucine Drugs 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 206010025135 lupus erythematosus Diseases 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 210000000822 natural killer cell Anatomy 0.000 description 3
• 238000011275 oncology therapy Methods 0.000 description 3
• 210000000287 oocyte Anatomy 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• 102000020233 phosphotransferase Human genes 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 238000001959 radiotherapy Methods 0.000 description 3
• 230000007115 recruitment Effects 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 102220126961 rs369936288 Human genes 0.000 description 3
• 102220036871 rs587780095 Human genes 0.000 description 3
• 102220080600 rs797046116 Human genes 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 238000002741 site-directed mutagenesis Methods 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 235000002639 sodium chloride Nutrition 0.000 description 3
• 230000037439 somatic mutation Effects 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 238000012384 transportation and delivery Methods 0.000 description 3
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 229910052720 vanadium Inorganic materials 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 210000005253 yeast cell Anatomy 0.000 description 3
• BAAVRTJSLCSMNM-CMOCDZPBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanedioic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 BAAVRTJSLCSMNM-CMOCDZPBSA-N 0.000 description 2
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
• 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 208000003950 B-cell lymphoma Diseases 0.000 description 2
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 238000012286 ELISA Assay Methods 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 208000001640 Fibromyalgia Diseases 0.000 description 2
• 102100031351 Galectin-9 Human genes 0.000 description 2
• 101710121810 Galectin-9 Proteins 0.000 description 2
• 208000032612 Glial tumor Diseases 0.000 description 2
• 206010018338 Glioma Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 2
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 2
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 101710163270 Nuclease Proteins 0.000 description 2
• 206010034277 Pemphigoid Diseases 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 102000018594 Tumour necrosis factor Human genes 0.000 description 2
• 108050007852 Tumour necrosis factor Proteins 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 210000000612 antigen-presenting cell Anatomy 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 238000003149 assay kit Methods 0.000 description 2
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 229960000074 biopharmaceutical Drugs 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 210000002230 centromere Anatomy 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 238000011198 co-culture assay Methods 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 108091008034 costimulatory receptors Proteins 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 238000000432 density-gradient centrifugation Methods 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 229940039227 diagnostic agent Drugs 0.000 description 2
• 239000000032 diagnostic agent Substances 0.000 description 2
• 230000007783 downstream signaling Effects 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 238000002825 functional assay Methods 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 231100000304 hepatotoxicity Toxicity 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
• 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
• 229960003130 interferon gamma Drugs 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 210000002510 keratinocyte Anatomy 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• 230000007056 liver toxicity Effects 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 238000004020 luminiscence type Methods 0.000 description 2
• 208000037841 lung tumor Diseases 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
• 208000008795 neuromyelitis optica Diseases 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 238000010606 normalization Methods 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 210000003289 regulatory T cell Anatomy 0.000 description 2
• 102200132938 rs74315448 Human genes 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 231100000004 severe toxicity Toxicity 0.000 description 2
• 235000020183 skimmed milk Nutrition 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 102000055501 telomere Human genes 0.000 description 2
• 108091035539 telomere Proteins 0.000 description 2
• 210000003411 telomere Anatomy 0.000 description 2
• 108010032276 tyrosyl-glutamyl-tyrosyl-glutamic acid Proteins 0.000 description 2
• 229950005972 urelumab Drugs 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 239000003643 water by type Substances 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• RVNZEJNWTUDQSC-JOCHJYFZSA-N (2r)-n-(6-aminohexyl)-1-tridecanoylpyrrolidine-2-carboxamide Chemical compound CCCCCCCCCCCCC(=O)N1CCC[C@@H]1C(=O)NCCCCCCN RVNZEJNWTUDQSC-JOCHJYFZSA-N 0.000 description 1
• XSYUPRQVAHJETO-WPMUBMLPSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidaz Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XSYUPRQVAHJETO-WPMUBMLPSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 235000006491 Acacia senegal Nutrition 0.000 description 1
• 208000008190 Agammaglobulinemia Diseases 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 239000012114 Alexa Fluor 647 Substances 0.000 description 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 229940116741 CD137 agonist Drugs 0.000 description 1
• 102100027207 CD27 antigen Human genes 0.000 description 1
• 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
• 101150023103 CHI gene Proteins 0.000 description 1
• 201000002829 CREST Syndrome Diseases 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 102220640918 Cell division control protein 6 homolog_S54D_mutation Human genes 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 208000011038 Cold agglutinin disease Diseases 0.000 description 1
• 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 102220579904 E3 ubiquitin-protein ligase RING2_D56K_mutation Human genes 0.000 description 1
• 229940122558 EGFR antagonist Drugs 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 102100037362 Fibronectin Human genes 0.000 description 1
• 102000016359 Fibronectins Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
• 208000007465 Giant cell arteritis Diseases 0.000 description 1
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
• 108060003393 Granulin Proteins 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 206010019695 Hepatic neoplasm Diseases 0.000 description 1
• 102220564972 Hexokinase HKDC1_D54G_mutation Human genes 0.000 description 1
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
• 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
• 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
• 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102100037850 Interferon gamma Human genes 0.000 description 1
• 108010065805 Interleukin-12 Proteins 0.000 description 1
• 102000013462 Interleukin-12 Human genes 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 240000005265 Lupinus mutabilis Species 0.000 description 1
• 235000008755 Lupinus mutabilis Nutrition 0.000 description 1
• 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 1
• 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
• 238000000585 Mann–Whitney U test Methods 0.000 description 1
• 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
• 208000027530 Meniere disease Diseases 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 230000006051 NK cell activation Effects 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 201000011152 Pemphigus Diseases 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 102100029812 Protein S100-A12 Human genes 0.000 description 1
• 101710110949 Protein S100-A12 Proteins 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 102220475559 Radial spoke head 1 homolog_D56A_mutation Human genes 0.000 description 1
• 102000018120 Recombinases Human genes 0.000 description 1
• 108010091086 Recombinases Proteins 0.000 description 1
• 206010038111 Recurrent cancer Diseases 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 235000019095 Sechium edule Nutrition 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• 108091008035 T cell costimulatory receptors Proteins 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 208000001106 Takayasu Arteritis Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 244000261122 Torulopsis holmii Species 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
• 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 206010047112 Vasculitides Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 229940124675 anti-cancer drug Drugs 0.000 description 1
• 229940124650 anti-cancer therapies Drugs 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000006023 anti-tumor response Effects 0.000 description 1
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 238000002820 assay format Methods 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 208000006424 autoimmune oophoritis Diseases 0.000 description 1
• 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 description 1
• 239000012752 auxiliary agent Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 238000012575 bio-layer interferometry Methods 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 229930189065 blasticidin Natural products 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 150000001639 boron compounds Chemical class 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 208000000594 bullous pemphigoid Diseases 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 229940112822 chewing gum Drugs 0.000 description 1
• 235000015218 chewing gum Nutrition 0.000 description 1
• 238000011097 chromatography purification Methods 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
• 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 201000010989 colorectal carcinoma Diseases 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 201000003278 cryoglobulinemia Diseases 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 230000006240 deamidation Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 208000018554 digestive system carcinoma Diseases 0.000 description 1
• 239000012470 diluted sample Substances 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 231100000655 enterotoxin Toxicity 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 210000001508 eye Anatomy 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000019264 food flavour enhancer Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
• PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
• 238000006317 isomerization reaction Methods 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 230000001050 lubricating effect Effects 0.000 description 1
• 238000003468 luciferase reporter gene assay Methods 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 201000006512 mast cell neoplasm Diseases 0.000 description 1
• 208000006971 mastocytoma Diseases 0.000 description 1
• 108010082117 matrigel Proteins 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 208000021039 metastatic melanoma Diseases 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 210000000472 morula Anatomy 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 208000004235 neutropenia Diseases 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 210000001331 nose Anatomy 0.000 description 1
• 201000005737 orchitis Diseases 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 238000004091 panning Methods 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 239000000906 photoactive agent Substances 0.000 description 1
• 239000003504 photosensitizing agent Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 239000011698 potassium fluoride Substances 0.000 description 1
• 235000003270 potassium fluoride Nutrition 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 229940071643 prefilled syringe Drugs 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 210000004986 primary T-cell Anatomy 0.000 description 1
• 230000000861 pro-apoptotic effect Effects 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
• 210000005267 prostate cell Anatomy 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 230000006916 protein interaction Effects 0.000 description 1
• 231100000654 protein toxin Toxicity 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 231100000336 radiotoxic Toxicity 0.000 description 1
• 230000001690 radiotoxic effect Effects 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 238000003571 reporter gene assay Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 238000003202 restriction enzyme-based method Methods 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 238000002702 ribosome display Methods 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 102200037435 rs121908539 Human genes 0.000 description 1
• 102220091021 rs147984543 Human genes 0.000 description 1
• 102220244279 rs373241693 Human genes 0.000 description 1
• 102220269348 rs61747367 Human genes 0.000 description 1
• 102200065436 rs80356613 Human genes 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 238000007480 sanger sequencing Methods 0.000 description 1
• 229930182490 saponin Natural products 0.000 description 1
• 150000007949 saponins Chemical class 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 238000010187 selection method Methods 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 230000009919 sequestration Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 239000001117 sulphuric acid Substances 0.000 description 1
• 235000011149 sulphuric acid Nutrition 0.000 description 1
• 231100000617 superantigen Toxicity 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 206010043207 temporal arteritis Diseases 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 208000013076 thyroid tumor Diseases 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 231100000440 toxicity profile Toxicity 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
• 208000009174 transverse myelitis Diseases 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 230000004565 tumor cell growth Effects 0.000 description 1
• 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1